Kemp Doliver

Research Analyst at Brookline Capital Markets

Kemp Dolliver is the Director of Research and Senior Analyst at Brookline Capital Markets, specializing in healthcare sector research with deep coverage of innovative biopharmaceutical and medtech companies. He has covered companies such as Bellerophon Therapeutics (BLPH), delivering top-rated calls including a single-stock return of 355.5% and maintaining coverage on approximately 30 stocks with a diverse track record highlighted on platforms like TipRanks. Dolliver began his career in investment banking and portfolio management, including roles at Cowen, Avondale Partners, and Religare Capital before founding Cherrystone Hill Capital Management and joining Brookline; his work has been recognized four times in The Wall Street Journal’s “Best on the Street” survey. He holds a B.S. in Commerce from the University of Virginia’s McIntire School of Commerce, an MBA from UVA’s Darden School of Business, and serves on the McIntire Advisory Board.